Polysorbates as novel lipid-modulating candidates for reducing serum total cholesterol and low-density lipoprotein levels in hyperlipidemic C57BL/6J mice and rats

European Journal of Pharmacology

Volumn 660, Issue 2-3, 2011, Pages 468-475

  Li, Xiaorong ^a   Wang, Lijuan ^a   Li, Yuhang ^a   Ho, Yeung ^b   Yang, Dongxu ^a   Chen, Yi ^a   Hu, Xiaomin ^a   Xue, Ming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hyperlipidemia; Lipid modulation; Polysorbate

Indexed keywords

CHOLESTEROL; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY FATS; FEMALE; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; POLYSORBATES; RATS;

EID: 79956098273     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.027     Document Type: Article

References (37)

1. Barzi, F., Patel, A., Woodward, M., Lawes, C.M., Ohkubo, T., Gu, D., Lam, T.H., Ueshima, H., 2005. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific Region. Ann. Epidemiol. 15, 405-413.
2. Bonetti, P.O., Lerman, L.O., Lerman, A., 2003. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23, 168-175.
3. Bustos, C., Hernandez-Presa, M.A., Ortego, M., et al., 1998. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32, 2057-2064.
4. Cherng, J.Y., Shi, M.F., 2005. Preventing dyslipidemia by Chlorella pyrenoidosa in rats and hamsters after chronic high fat diet treatment. Life Sci. 76, 3001-3013.
5. Choudhary, M.I., Naheed, S., Jalil, S., Alam, J.M., Rahman, A., 2005. Effects of ethanolic extract of Iris germanica on lipid profile of rats fed ona high-fat diet. J. Ethnopharmacol. 98, 217-220. (Pubitemid 40349192)
6. Chinese Pharmacopeia Committee, 2010. Chinese Pharmacopeia, 2010 Revision, Ninth Edition. Chinese Publishing House of Medicinal Technology, Beijing, pp. 1244-1247.
7. Daher, C.F., Baroody, G.M., Howland, R.J., 2003. Effect of a surfactant, polysorbate, on the formation and secretion of chylomicrons in the rat. Food Chem. Toxicol. 41, 575-582.
8. Davidson, M.H., Dillon, M.A., Gordon, B., et al., 1999. Colesevelam hydrochloride cholestagel: a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. 159, 1893-1900.
9. Dobiásová,M., Frohlich, J., 2001. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoBlipoprotein- depleted plasma. Clin. Biochem. 34, 583-588.
10. Drexler, H., Horning, B.D., 1999. Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 31, 51-60.
11. Elaine, B., Feldman, M.D., Charles, Y., Cheng, B.S., 1975. Mucosal uptake in vitro of cholesterol from bile salt and surfactant solutions. Am. J. Clin. Nutr. 28, 692-698.
12. Farias, R.A.F., Neto, M.F.O., Viana, G.S.B., Rao, V.S.N.I., 1996. Effects of Croton cajucara extract on serum lipids of rats fed a high fat diet. Phytother. Res. 10, 697-699.
13. Ghasi, S., Nwobodo, E., Ofili, J.O., 2000. Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam. in high-fat diet fed Wistar rats. J. Ethnopharmacol. 69, 21-25. (Pubitemid 29505288)
14. Gordon, T., Kannel, W.B., Castelli, W.P., Dawber, T.R., 1981. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch. Intern. Med. 141, 1128-1131.
15. Grundy, S.M., 1986. Cholesterol and coronary heart disease: a new era. J. Am. Med. Assoc. 256, 2849-2858.
16. Hayashidani, S., Tsutsui, H., Shiomi, T., Suematsu, N., Kinugawa, N., Ide, T., et al., 2002. Fluvastatin, a 3-hyroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105, 868-873. (Pubitemid 34174929)
17. Heron, M., 2007. Deaths: leading causes for 2004. Natl. Vital Stat. Rep. 56, 1-95.
18. Hisae, K., Keiko, T., Keiko, O., Hajime, S., 2006. Ethanolamine improves hypercholesterolemia in rats fed high-fat/high-cholesterol diets. Nutr. Res. 26, 573-578.
19. Holmes, D.T., Frohlich, J., Buhr, K.A., 2008. The concept of precision extended to the atherogenic index of plasma. Clin. Biochem. 41, 631-635.
20. Kamisako, T., Ogawa, H., Yamamoto, K., 2007. Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat. J. Gastroenterol. Hepatol. 22, 1832-1837.
21. Koh, K.K., 2000. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res. 47, 648-657.
22. Koruk, M., Savas, M.C., Yilmaz, O., Taysi, S., Karakok, M., Gndgdu, C., Yilmaz, A., 2003. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 37, 177-182.
23. Lacoste, L., Lam, J.Y., Hung, J., et al., 1995. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92, 3172-3177.
24. LaRosa, J.C., Grundy, S.M., Waters, D.D., Shear, C., Barter, P., Fruchart, J.C., Gotto, A.M., Greten, H., Kastelein, J.J., Shepherd, J., Wenger, N.K., 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435.
25. Laufs, U., Liao, J.K., 1998. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271.
26. Lefer, D.J., 2002. Statins as potent anti-inflammatory drugs. Circulation 106, 2041-2042.
27. Mariarosaria, S., Angelo,M., Paolo, M., Chiara, L., Simona, D., Stefania, S., Laura, F., Adriana, A., Mario, V., Maurizio, B., 1999. Dietary and hypothyroid hypercholesterolemia induces hepatic apolipo-protein E expression in the rat: direct role of cholesterol. FEBS Lett. 463, 83-86.
28. Michalis, K., Vasilis, T., Moses, E., 2010. Pleiotropic effects of ezetimibe: do they really exist. Eur. J. Pharmacol. 633, 62-70.
29. Milada, D.O., Frohlich, J., 2001. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapoblipoprotein- depleted plasma. Clin. Biochem. 34, 583-588.
30. National Toxicology Program, 1992. NTP toxicology and carcinogenesis studies of polysorbate 80 (CAS No. 9005-65-6) in F344/N rats and B6C3F1 mice (feed studies). Nat. Toxicol. Program Tech. Rep. Ser. 415, 1-225.
31. Ogilvie, G.K., Cockburn, C.A., Tranquilli, W.J., Reschke, R.W., Weigel, R.M., 1988. Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog. Am. J. Vet. Res. 49, 1367-1370.
32. Shigeru, M., Yukiko, K.O., Kazuyuki, T., 1999. Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci. 64, 83-91.
33. Vazques-Freire, M.J., Lamela, M., Calleja, J.M., 1996. Hypolipidaemic activity of a polysaccharide extract from Fucus vesiculosus L. Phytother. Res. 10, 647-650.
34. Wang, L.J., Li, X.R., Li, Y.H., Xu, Y.X., 2007. Dynamic observation of serum lipid and ALT levels in C57BL/6J mice models of hyperlipidemia induced by high-lipid diet. Chin. J. Comp. Med. 17, 572-575.
35. Yang, X.Y., Yang, Y.Z., Tan, J.M., Yuan, Z.H., Wan, Z.Y., 1996. The establishment of an atherosclerotic murine model and pathological observation of plaques by laser scanning confocal microscopy. Chin. J. Arterioscler. 4 (1), 54-57.
36. Yusuf, S., 2002. Two decades of progress in preventing vascular disease. Lancet 360, 2-3. (Pubitemid 34756482)
37. Zimmermann, M., 1983. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16, 109-110. (Pubitemid 13058546)